文献速递胃肠动力与功能性疾病

随机临床试验:ONO-2952治疗腹泻型肠易激综合征的探索性2期研究

Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-07

在49个美国中心开展的随机、双盲、安慰剂对照探索性概念验证研究,纳入200例符合罗马III标准的腹泻型肠易激综合征女性,随机接受ONO-2952 20 mg、60 mg或安慰剂治疗4周。符合方案分析中三个共同主要终点均见ONO-2952优于安慰剂的改善,但未达5%水平的统计学显著,60 mg组改善最大;安全性与安慰剂相似。

要点

  • 符合方案分析中ONO-2952在腹痛、大便性状、大便频率三个共同主要终点均优于安慰剂,但未达统计学显著。
  • ONO-2952 60 mg组症状改善幅度最大,总体耐受性良好,安全性特征与安慰剂相似。
  • 作者认为该药在减少女性腹泻型肠易激综合征相关症状方面有临床疗效证据,需进一步评估。

核心结论

  • ONO-2952在减少女性腹泻型肠易激综合征相关症状方面显示出临床疗效证据,因此需要进一步评估其作为腹泻型肠易激综合征治疗的潜力(NCT01844180)。

研究设计与样本

  • 随机、双盲、安慰剂对照的探索性概念验证研究,在美国49个中心开展。
  • 纳入200例符合罗马III标准的腹泻型肠易激综合征受试者,随机分为ONO-2952 20 mg组、60 mg组或安慰剂组。
  • 受试者在2周基线期、4周治疗期及治疗后4周内每日记录肠易激综合征症状。
  • 共同主要终点为第4周腹痛、大便性状和大便频率相对基线的变化。

主要发现

  • 符合方案分析中,ONO-2952在全部三个共同主要终点上均较安慰剂改善肠易激综合征症状,但在5%水平未达统计学显著。
  • ONO-2952 60 mg组观察到的改善最大。
  • ONO-2952耐受性良好,安全性特征与安慰剂相似。
  • 大多数不良事件为轻或中度,且与治疗无关。

临床怎么用

  • 作者认为ONO-2952在减少女性腹泻型肠易激综合征相关症状方面有临床疗效证据,并认为需进一步评估其治疗潜力。

局限性

  • 原文报告三个共同主要终点的改善未达5%水平的统计学显著,并指出需要进一步评估ONO-2952的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ONO-2952 is a novel and selective inhibitor of translocator protein 18 kDa that reduces stress-induced defecation and visceral hyperalgesia in rat models. AIM: To evaluate the efficacy and safety of ONO-2952 in females with irritable bowel syndrome with diarrhoea in an exploratory proof-of-concept study. METHODS: A randomised, double-blind, placebo-controlled study was conducted at 49 US centres. Two hundred subjects with irritable bowel syndrome with diarrhoea (Rome III criteria) were randomised to ONO-2952 20 mg, or 60 mg, or placebo. Subjects recorded irritable bowel syndrome symptoms daily during a 2-week baseline period, the 4-week treatment period and for 4 weeks post-treatment. The co-primary endpoints were change from baseline to week 4 in abdominal pain, stool consistency and stool frequency. RESULTS: Improvements in irritable bowel syndrome symptoms were seen with ONO-2952 over placebo in per-protocol analyses for all three co-primary endpoints, but these did not reach statistical significance at the 5% level. The largest improvement was seen with ONO-2952 60 mg. ONO-2952 was well tolerated with a safety profile similar to that of placebo. Most adverse events were mild or moderate in severity and not treatment related. CONCLUSION: ONO-2952 showed evidence of clinical efficacy in reducing irritable bowel syndrome-related symptoms in female subjects with irritable bowel syndrome with diarrhoea, and further evaluation is, therefore, warranted to assess its potential as a treatment for irritable bowel syndrome with diarrhoea (NCT01844180).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Whitehead WE, Duffy K, Sharpe J, et al. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016. PMID: 27910150. doi:10.1111/apt.13839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。